share_log

Intelligent Bio Solutions | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(4.9%),Ionic Management, LLC(4.9%), etc.

Intelligent Bio Solutions | SC 13G/A：超過5%持股股東披露文件(修正)-Ionic Ventures, LLC(4.9%),Ionic Management, LLC(4.9%)等

美股sec公告 ·  02/14 18:09
Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement...Show More
Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement to file this amendment jointly in accordance with SEC regulations. The filing also notes that the shares of common stock reported are based on 2,147,789 outstanding shares as disclosed in the company's Quarterly Report on Form 10-Q for the period ended December 31, 2023, and do not fully account for shares issuable upon the exercise of Series G warrants subject to a beneficial ownership blocker.
Intelligent Bio Solutions Inc.已成爲2024年2月14日向美國證券交易委員會（SEC）提交的修訂文件的主題。該文件是附表13G聲明的第1號修正案，表明Ionic Ventures LLC、Ionic Management LLC以及個人Keith Coulston和Brendan O'Neil（統稱爲 “申報人”）已不再是該公司超過5％的已發行普通股的受益所有人。該修正案用作申報人的出境申報。考慮到2024年1月26日生效的每12股反向股票拆分，有關股票總額爲112,803股，佔公司證券類別的4.9％。申報人已簽訂聯合申報協議，根據美國證券交易委員會的規定共同提交該修正案。該文件還指出，報告的普通股基於該公司截至2023年12月31日的10-Q表季度報告中披露的2,147,789股已發行股票，並未完全考慮行使受實所有權封鎖的G系列認股權證時可發行的股票。
Intelligent Bio Solutions Inc.已成爲2024年2月14日向美國證券交易委員會（SEC）提交的修訂文件的主題。該文件是附表13G聲明的第1號修正案，表明Ionic Ventures LLC、Ionic Management LLC以及個人Keith Coulston和Brendan O'Neil（統稱爲 “申報人”）已不再是該公司超過5％的已發行普通股的受益所有人。該修正案用作申報人的出境申報。考慮到2024年1月26日生效的每12股反向股票拆分，有關股票總額爲112,803股，佔公司證券類別的4.9％。申報人已簽訂聯合申報協議，根據美國證券交易委員會的規定共同提交該修正案。該文件還指出，報告的普通股基於該公司截至2023年12月31日的10-Q表季度報告中披露的2,147,789股已發行股票，並未完全考慮行使受實所有權封鎖的G系列認股權證時可發行的股票。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息